Go Pro

Cencora (COR) Stock Price, News & Analysis

Cencora logo
$313.86 +3.85 (+1.24%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$313.21 -0.64 (-0.20%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cencora Stock (NYSE:COR)

Advanced

Key Stats

Today's Range
$302.01
$314.31
50-Day Range
$271.14
$333.21
52-Week Range
$244.82
$377.54
Volume
1.52 million shs
Average Volume
1.56 million shs
Market Capitalization
$59.89 billion
P/E Ratio
23.32
Dividend Yield
0.76%
Price Target
$374.25
Consensus Rating
Moderate Buy

Company Overview

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers. These services include commercialization support, market access and reimbursement consulting, patient hub and adherence programs, specialty pharmacy management, and clinical support services that help bring specialty and high-cost therapies to market and to patients efficiently.

Cencora operates across multiple geographies with a network of distribution centers, specialty pharmacies and logistics facilities that serve hospitals, health systems, retailers, independent pharmacies, physician practices and manufacturers. The company’s infrastructure and service model are geared toward handling both high-volume commodity products and complex specialty medicines, including oncology, rare disease and biologic therapies.

The company was formed through the rebranding of AmerisourceBergen in 2023 and is headquartered in Conshohocken, Pennsylvania. It is led by Steven H. Collis, who has served as chief executive officer since 2011. Cencora’s business model emphasizes integrated supply chain capabilities and services that support pharmaceutical manufacturers, payers and providers in delivering therapies to patients.

AI Generated. May Contain Errors.

Cencora Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
99th Percentile Overall Score

COR MarketRank™: 

Cencora scored higher than 99% of companies evaluated by MarketBeat, and ranked 6th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on no strong buy ratings, 13 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Cencora has a consensus price target of $374.25, representing about 19.2% upside from its current price of $313.86.

  • Amount of Analyst Coverage

    Cencora has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cencora's stock forecast and price target.
  • Earnings Growth

    Earnings for Cencora are expected to grow by 10.82% in the coming year, from $17.84 to $19.77 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cencora is 23.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.94.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cencora is 23.32, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.27.

  • Price to Earnings Growth Ratio

    Cencora has a PEG Ratio of 1.78. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Cencora has a P/B Ratio of 18.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.66% of the float of Cencora has been sold short.
  • Short Interest Ratio / Days to Cover

    Cencora has a short interest ratio ("days to cover") of 4.17.
  • Change versus previous month

    Short interest in Cencora has recently decreased by 12.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cencora has a dividend yield of 0.77%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Cencora has been increasing its dividend for 15 years.

  • Dividend Coverage

    The dividend payout ratio of Cencora is 17.83%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Cencora will have a dividend payout ratio of 12.14% next year. This indicates that Cencora will be able to sustain or increase its dividend.

  • Read more about Cencora's dividend.
  • News Sentiment

    Cencora has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 23 news articles for Cencora this week, compared to 8 articles on an average week.
  • Search Interest

    14 people have searched for COR on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cencora insiders have bought more of their company's stock than they have sold. Specifically, they have bought $148,626.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    0.38% of the stock of Cencora is held by insiders.

  • Percentage Held by Institutions

    97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cencora's insider trading history.
Receive COR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COR Stock News Headlines

Cencora (COR) Gets a Buy from Evercore ISI
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
Cencora Announces Resignation of Board Member Lorence Kim
Wells Fargo Gives a Buy Rating to Cencora (COR)
Is Wall Street bullish or bearish on Cencora stock?
Cardinal Health branded boxes on pallets sit amid automated conveyor systems in a distribution warehouse.
Cardinal Health Earnings: Can Perfection Get Priced In Twice? (COR)
Cardinal Health stock hit a new all-time high after mixed earnings, with analyst price target hikes, gene therapy logistics wins and a 29-year dividend growth streak supporting the uptrend.
McKesson distribution facility exterior at dusk, showing branded trucks at loading docks and a glass-walled warehouse interior.
McKesson's Compounding Keeps Adding Up (COR)
McKesson posted strong fiscal 2026 results, raised guidance, boosted buybacks and its dividend, and maintains a Moderate Buy rating from analysts amid its evolving specialty business mix.
See More Headlines

COR Stock Analysis - Frequently Asked Questions

Cencora's stock was trading at $338.07 at the start of the year. Since then, COR stock has decreased by 7.2% and is now trading at $313.8580.

Cencora, Inc. (NYSE:COR) announced its quarterly earnings data on Wednesday, August, 5th. The company reported $4.48 EPS for the quarter, topping analysts' consensus estimates of $4.35 by $0.13. Cencora's revenue for the quarter was up 5.1% compared to the same quarter last year.
Read the conference call transcript
.

Cencora's Board of Directors approved a stock buyback program on Thursday, May 21st 2026, which authorizes the company to repurchase $2,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 3.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board believes its stock is undervalued.

Cencora subsidiaries include Alliance Healthcare, H. D. Smith, St. Francis Group, PharMEDium Healthcare, MWI Veterinary Supply, World Courier, IntrinsiQ, and more.

Top institutional shareholders of Cencora include BlackRock Inc. (9.36%), Mitsubishi UFJ Asset Management Co. Ltd. (0.88%), Legal & General Group Plc (0.62%) and The Manufacturers Life Insurance Company (0.57%). Insiders that own company stock include Walgreens Boots Alliance, Inc, Steven H Collis, Robert P Mauch, Robert P Mauch, Elizabeth S Campbell, Dermot Mark Durcan, Lazarus Krikorian, Silvana Battaglia, Gina Clark, Gina Clark, Leslie E Donato, Leslie E Donato and Lauren M Tyler.
View institutional ownership trends
.

Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cencora investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Broadcom (AVGO), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

Record date for 6/1 Dividend
5/15/2026
Ex-Dividend for 6/1 Dividend
5/15/2026
Dividend Payable
6/01/2026
Last Earnings
8/05/2026
Record date for 8/31 Dividend
8/14/2026
Ex-Dividend for 8/31 Dividend
8/14/2026
Today
8/15/2026
Dividend Payable
8/31/2026
Fiscal Year End
9/30/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Distributors
Current Symbol
NYSE:COR
CIK
1140859
Employees
51,000
Year Founded
2001

Price Target and Rating

High Price Target
$440.00
Low Price Target
$285.00
Potential Upside/Downside
+19.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
$13.46
Trailing P/E Ratio
23.32
Forward P/E Ratio
17.59
P/E Growth
1.8
Net Income
$1.55 billion
Net Margins
0.79%
Pretax Margin
1.08%
Return on Equity
125.45%
Return on Assets
4.18%

Debt

Debt-to-Equity Ratio
3.53
Current Ratio
0.93
Quick Ratio
0.58

Sales & Book Value

Annual Sales
$321.33 billion
Price / Sales
0.19
Cash Flow
$21.62 per share
Price / Cash Flow
14.52
Book Value
$16.97 per share
Price / Book
18.49

Miscellaneous

Outstanding Shares
190,830,000
Free Float
190,102,000
Market Cap
$59.89 billion
Optionable
Optionable
Beta
0.57

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NYSE:COR) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners